Cargando…
Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747695/ https://www.ncbi.nlm.nih.gov/pubmed/15328518 http://dx.doi.org/10.1038/sj.bjc.6602089 |
_version_ | 1782172116880195584 |
---|---|
author | Mineo, J-F Bordron, A Quintin-Roué, I Loisel, S Ster, K L Buhé, V Lagarde, N Berthou, C |
author_facet | Mineo, J-F Bordron, A Quintin-Roué, I Loisel, S Ster, K L Buhé, V Lagarde, N Berthou, C |
author_sort | Mineo, J-F |
collection | PubMed |
description | Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth. Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not (U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin®). Human epithelial receptor type 2/neu expression was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors. |
format | Text |
id | pubmed-2747695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27476952009-09-21 Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas Mineo, J-F Bordron, A Quintin-Roué, I Loisel, S Ster, K L Buhé, V Lagarde, N Berthou, C Br J Cancer Experimental Therapeutics Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth. Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not (U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin®). Human epithelial receptor type 2/neu expression was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors. Nature Publishing Group 2004-09-13 2004-08-24 /pmc/articles/PMC2747695/ /pubmed/15328518 http://dx.doi.org/10.1038/sj.bjc.6602089 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Experimental Therapeutics Mineo, J-F Bordron, A Quintin-Roué, I Loisel, S Ster, K L Buhé, V Lagarde, N Berthou, C Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas |
title | Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas |
title_full | Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas |
title_fullStr | Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas |
title_full_unstemmed | Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas |
title_short | Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas |
title_sort | recombinant humanised anti-her2/neu antibody (herceptin®) induces cellular death of glioblastomas |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747695/ https://www.ncbi.nlm.nih.gov/pubmed/15328518 http://dx.doi.org/10.1038/sj.bjc.6602089 |
work_keys_str_mv | AT mineojf recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas AT bordrona recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas AT quintinrouei recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas AT loisels recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas AT sterkl recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas AT buhev recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas AT lagarden recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas AT berthouc recombinanthumanisedantiher2neuantibodyherceptininducescellulardeathofglioblastomas |